Skip to main content
. 2013 May 9;108(10):2153–2163. doi: 10.1038/bjc.2013.212

Table 2a. Molecular characteristics of colorectal cancer cases in the NSHDS cohort.

  N MSI MSS P-value CIMP-negative CIMP-low CIMP-high P-value
Frequency (%)
197
24 (12.2)
173 (87.8)
 
97 (50.0)
70 (36.1)
27 (13.9)
 
Quadruple Index
 
 
 
0.384
 
 
 
0.002
Negative 89 (51.7) 9 (42.9) 80 (53.0)   52 (61.9) 31 (50.0) 6 (23.1)  
Positive
83 (48.3)
12 (57.1)
71 (47.0)
 
32 (38.1)
31 (50.0)
20 (76.9)
 
KRAS
 
 
 
0.031
 
 
 
0.046
Wt 147 (82.1) 19 (100.0) 128 (80.0)   68 (79.1) 52 (78.8) 24 (100.0)  
Mutant
32 (17.9)
0 (0.0)
32 (20.0)
 
18 (20.9)
14 (21.2)
0 (0.0)
 
BRAF
 
 
 
<0.0001
 
 
 
<0.0001
Wt 161 (82.1) 13 (54.2) 148 (86.0)   93 (96.9) 57 (81.4) 8 (29.6)  
Mutant
35 (17.9)
11 (45.8)
24 (14.0)
 
3 (3.1)
13 (18.6)
19 (70.4)
 
PIK3CA Exon20
 
 
 
0.448
 
 
 
0.670
Wt 182 (97.8) 23 (100.0) 159 (97.5)   91 (97.8) 63 (96.9) 25 (100.0)  
Mutant
4 (2.2)
0 (0.0)
4 (2.5)
 
2 (2.2)
2 (3.1)
0 (0.0)
 
PTEN       1.000       0.641
Normal 161 (87.5) 21 (87.5) 140 (87.5)   80 (86.0) 58 (90.6) 23 (85.2)  
Loss 23 (12.5) 3 (12.5) 20 (12.5)   13 (14.0) 6 (9.4) 4 (14.8)  

Abbreviations: CIMP=CpG island methylator phenotype; MSS=microsatellite stable; NSHDS=Northern Sweden Health Disease Study; MSI=microsatellite instability; Wt=wild-type.

The following numbers of missing cases were present in NSHDS: CIMP status, 3; Quadruple Index, 25; KRAS mutation status, 18; BRAF mutation status, 1; PIK3CA mutation status, 11; PTEN mutation status, 13. Cases lacking nuclear staining of tumour cells for at least one of MLH1, MSH2, MSH6 or PMS2 were considered to have a positive MSI screening status (MSI). CIMP according to an eight-gene panel including CDKN2A, hMLH1, CACNA1G, NEUROG1, RUNX3, SOCS1, IGF2 and CRABP1; CIMP-negative, 0 genes hypermethylated; CIMP-low, 1–5 genes hypermethylated; CIMP-high, 6–8 genes hypermethylated. Kruskall–Wallis test was used for continuous variables, χ2-test or Fisher's exact test used for categorical variables.